A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer-Reference-Cited by-同舟云学术

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

Published:2010-02-10 Issue:7 Volume:59 Page:1001-1009
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Noguchi Masanori,Kakuma Tatsuyuki,Uemura Hirotsugu,Nasu Yasutomo,Kumon Hiromi,Hirao Yasuhiko,Moriya Fukuko,Suekane Shigetaka,Matsuoka Kei,Komatsu Nobukazu,Shichijo Shigeki,Yamada Akira,Itoh Kyogo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-010-0822-4.pdf

Reference25 articles.

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66

2. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238–244

3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1488–1490

4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

5. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM, Melief CJ (2000) Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23:255–266

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Trends in Immunotherapy for Adult Sarcomas;The Oncologist;2023-03-11

2. Vaccines as treatments for prostate cancer;Nature Reviews Urology;2023-03-06

3. From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy;Frontiers in Chemistry;2023-01-17

4. Current status and progress of the development of prostate cancer vaccines;Journal of Cancer;2023

5. Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer;Cancers;2021-01-06